DNA Fingerprinting Assays Run on Integrated ZyGEM/MicroLab Sample-to-Answer Platform Have Transformational Potential for Profiling Unknown Bacterial Samples Has Potential to Identify Up to 30 Different Bacterial Infectious Agents in Challenging Samples in Less than One Hour, a Dramatic Improvement over Current Methods Charlottesville, VA and Hamilton, New Zealand – ZyGEM Corp. Ltd., has introduced its […]
CINCINNATI – Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene(TM) C.difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay […]
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN’s wholly owned subsidiary […]
AUSTIN, Tex and CARLSBAD, Calif. – Asuragen, Inc. and Life Technologies Corporation (NASDAQ: LIFE) announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen’s clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). […]
Easy-to-use molecular test offers faster results to help healthcare facilities control spread of methicillin-resistant Staphylococcus aureus (MRSA) Basel – Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical […]
Preclinical Animal Data Demonstrates Promising Stem Cell Therapeutic Strategy for HIV/AIDS – Extends ZFP Therapeutic Application RICHMOND, Calif. – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. […]
Dortmund, Germany – Protagen AG, Dortmund, and the Neuried, Germany, based diagnostics company Mikrogen GmbH, announced today the closing of a collaboration agreement for the identification of typical autoantibody signatures in infectious diseases. Also classical infectious disease diagnostics can benefit from UNIarray®, the proprietary technology platform of Protagen for the determination of indication specific autoantibody […]
Signature Diagnostics Will Commercialize First Microarray-Based Products for Detecting and Predicting Progression of Colorectal Cancer Santa Clara, Calif. & Postdam, Germany – Affymetrix, Inc. (NASDAQ:AFFX) and Signature Diagnostics AG (Signature Dx) today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix(R) […]
RUNCORN, Cheshire – Thermo Fisher Scientific Inc., the world leader in serving science, today announced its latest STP 420ES tissue processor for use in high-volume pathology laboratories. The updated instrument features more robust hardware and ease-of-use, enabling the high-throughput processing of large volumes of tissue to meet the demands of today’s laboratories. The Thermo Scientific […]
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”), today announced that it has granted a non-exclusive license to BD (Becton, Dickinson and Company) to use Exiqon’s proprietary locked nucleic acids (LNA™) technology in defined products for infectious disease diagnostics. Exiqon will receive upfront and milestone payments, and royalty on global sales of the products covered by this […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
